Accumulating evidence in the literature on CML and other illnesses treated with IFNs points to the relative safety of gonadal and pregnancy IFN exposure in terms of maternal and fetal outcomes [9]. Here, IFNA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.